ÂÜÀòÂÒÂ×

Mike Nahorski currently serves as the Director of Strategic Accounts and Director of Clinical & Scientific Alliances at NeoGenomics Laboratories, where responsibilities include overseeing the launch of the ctDNA-based Minimal Residual Disease detection assay, RaDaR, as well as engaging with external key opinion leaders and supporting medical affairs teams. Previously, Mike worked as a Medical Science Liaison at Eli Lilly and Company, focusing on pre-launch and launch activities for a pain product across several Nordic countries and the UK. Additionally, Mike served as a Postdoctoral Research Associate at the University of Cambridge, where research involved identifying mutations associated with pain. Educational background includes a Ph.D. in Molecular Genetics of Inherited Renal Cancer from the University of Birmingham.